CTU: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

  • Veitch, Elizabeth (Primary Chief Investigator)
  • Morrisroe, Emma (Clinical Trial Unit Staff)
  • Contacos, Christine (Clinical Trial Unit Staff)
  • Chester, Catherine (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

Short title1305-0023
AcronymFIBRONEERTM – ILD
StatusActive
Effective start/end date8/06/23 → 23/02/26